Overview of Hepatitis B and C

by

Hepatitis B and C are viral infections that affect the liver and require antiviral therapy for management. Understanding the differences between the antivirals used for each type is essential for pharmacy practice, ensuring appropriate medication counseling and patient safety.

Overview of Hepatitis B and C

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are bloodborne pathogens that can lead to chronic liver disease, cirrhosis, and hepatocellular carcinoma. While both affect the liver, their virology, transmission, and treatment strategies differ significantly.

Antiviral Agents for Hepatitis B

Hepatitis B antivirals primarily include nucleos(t)ide analogues that inhibit viral DNA replication. Common agents include tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir, and lamivudine. These medications suppress viral replication but rarely eradicate the virus entirely.

Key Characteristics of HBV Antivirals

  • Mechanism of Action: Inhibition of reverse transcriptase enzyme, preventing viral DNA synthesis.
  • Resistance: Lamivudine has higher resistance rates; newer agents like tenofovir and entecavir have lower resistance profiles.
  • Duration of Therapy: Often long-term, sometimes lifelong, to suppress viral replication.

Antiviral Agents for Hepatitis C

HCV antivirals have evolved significantly, with direct-acting antivirals (DAAs) now offering high cure rates. These include agents such as sofosbuvir, ledipasvir, velpatasvir, glecaprevir, and pibrentasvir, often used in combination regimens.

Key Characteristics of HCV Antivirals

  • Mechanism of Action: Target specific viral proteins like NS5A, NS5B polymerase, and protease enzymes.
  • Resistance: Resistance can develop but is less common with combination therapy.
  • Duration of Therapy: Typically 8 to 12 weeks, with high cure rates (>95%).

Differences in Pharmacology and Practice

While both types of antivirals aim to suppress viral activity, their pharmacological profiles and clinical considerations differ. HBV treatments often require lifelong therapy, whereas HCV treatments are usually finite courses. Resistance patterns, monitoring requirements, and drug interactions also vary.

Monitoring and Safety

  • HBV: Regular liver function tests, renal function monitoring (especially with tenofovir).
  • HCV: Monitoring for drug interactions and adherence during therapy.

Implications for Pharmacy Practice

Pharmacists play a vital role in ensuring appropriate antiviral selection, patient education, adherence support, and monitoring for adverse effects. Recognizing the differences in therapy duration, resistance, and monitoring helps optimize patient outcomes and prevent complications.

Patient Counseling Tips

  • Explain the importance of adherence, especially for lifelong HBV therapy.
  • Discuss potential side effects, such as renal impairment with tenofovir or fatigue with DAAs.
  • Encourage regular monitoring and follow-up appointments.

Understanding the distinct characteristics of hepatitis B and C antivirals enhances the pharmacist’s ability to provide comprehensive care and support effective treatment strategies.